Literature DB >> 1627826

Sequence analysis of the large and small subunits of human ribonucleotide reductase.

N Pavloff1, D Rivard, S Masson, S H Shen, A M Mes-Masson.   

Abstract

We have isolated and sequenced overlapping cDNA clones from a breast carcinoma cDNA library containing the entire coding region of both the R1 and R2 subunits of the human ribonucleotide reductase gene. The coding region of the human R1 subunit comprises 2376 nucleotides and predicts a polypeptide of 792 amino acids (calculated molecular mass 90,081). The sequence of this subunit is almost identical to the equivalent mouse ribonucleotide reductase subunit with 97.7% homology between the mouse and human R1 subunit amino acid sequences. The coding region of the human R2 subunit of ribonucleotide reductase comprises 1170 nucleotides and predicts a polypeptide of 389 amino acids (calculated molecular mass 44,883), which is one amino acid shorter than the equivalent mouse subunit. The human and mouse R2 subunits display considerable homology in their carboxy-terminal amino acid sequences, with 96.3% homology downstream of amino acid 68 of the human and mouse R2 proteins. However, the amino-terminal portions of these two proteins are more divergent in sequence, with only 69.2% homology in the first 68 amino acids.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1627826     DOI: 10.3109/10425179209020807

Source DB:  PubMed          Journal:  DNA Seq        ISSN: 1026-7913


  9 in total

1.  New nucleotide sequence data on the EMBL File Server.

Authors: 
Journal:  Nucleic Acids Res       Date:  1992-06-11       Impact factor: 16.971

2.  Enhanced subunit interactions with gemcitabine-5'-diphosphate inhibit ribonucleotide reductases.

Authors:  Jun Wang; Gregory J S Lohman; JoAnne Stubbe
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-28       Impact factor: 11.205

3.  Overexpression of transfected human ribonucleotide reductase M2 subunit in human cancer cells enhances their invasive potential.

Authors:  B S Zhou; P Tsai; R Ker; J Tsai; R Ho; J Yu; J Shih; Y Yen
Journal:  Clin Exp Metastasis       Date:  1998-01       Impact factor: 4.510

4.  Identification of genes expressed in premalignant breast disease by microscopy-directed cloning.

Authors:  R A Jensen; D L Page; J T Holt
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-27       Impact factor: 11.205

5.  Cloning, sequence determination, and regulation of the ribonucleotide reductase subunits from Plasmodium falciparum: a target for antimalarial therapy.

Authors:  H Rubin; J S Salem; L S Li; F D Yang; S Mama; Z M Wang; A Fisher; C S Hamann; B S Cooperman
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-15       Impact factor: 11.205

6.  A Missense Mutation in a Large Subunit of Ribonucleotide Reductase Confers Temperature-Gated Tassel Formation.

Authors:  Shiyi Xie; Hongbing Luo; Yumin Huang; Yaxin Wang; Wei Ru; Yunlu Shi; Wei Huang; Hai Wang; Zhaobin Dong; Weiwei Jin
Journal:  Plant Physiol       Date:  2020-10-05       Impact factor: 8.340

7.  Defining a novel cis element in the 3'-untranslated region of mammalian ribonucleotide reductase component R2 mRNA: role in transforming growth factor-beta 1 induced mRNA stabilization.

Authors:  F M Amara; F Y Chen; J A Wright
Journal:  Nucleic Acids Res       Date:  1995-05-11       Impact factor: 16.971

Review 8.  Therapeutic Value of Single Nucleotide Polymorphisms on the Efficacy of New Therapies in Patients with Multiple Sclerosis.

Authors:  María José Zarzuelo Romero; Cristina Pérez Ramírez; María Isabel Carrasco Campos; Almudena Sánchez Martín; Miguel Ángel Calleja Hernández; María Carmen Ramírez Tortosa; Alberto Jiménez Morales
Journal:  J Pers Med       Date:  2021-04-23

9.  The expression of glyceraldehyde-3-phosphate dehydrogenase associated cell cycle (GACC) genes correlates with cancer stage and poor survival in patients with solid tumors.

Authors:  Dunrui Wang; Daniel R Moothart; Douglas R Lowy; Xiaolan Qian
Journal:  PLoS One       Date:  2013-04-19       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.